Regeneron Pharmaceuticals (REGN)
Market Price (7/31/2026): $735.0 | Market Cap: $75.6 BilInvestor Relations Sector: Health Care | Industry: Biotechnology
Regeneron Pharmaceuticals (REGN)
Market Price (7/31/2026): $735.0Market Cap: $75.6 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.2% Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 27% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 23%, CFO LTM is 4.7 Bil, FCF LTM is 3.6 Bil Stock buyback supportStock Buyback 3Y Total is 11 Bil Low stock price volatilityVol 12M is 34% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. | Weak multi-year price returns2Y Excs Rtn is -68%, 3Y Excs Rtn is -61% | Key risksREGN key risks include [1] the erosion of flagship Eylea revenue from imminent biosimilar competition following patent expirations, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.2% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 27% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 23%, CFO LTM is 4.7 Bil, FCF LTM is 3.6 Bil |
| Stock buyback supportStock Buyback 3Y Total is 11 Bil |
| Low stock price volatilityVol 12M is 34% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -68%, 3Y Excs Rtn is -61% |
| Key risksREGN key risks include [1] the erosion of flagship Eylea revenue from imminent biosimilar competition following patent expirations, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Regeneron Pharmaceuticals (REGN) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Continued weakness and competitive pressures impacted the Eylea franchise.
In fiscal Q1 2026, reported on April 29, 2026, total U.S. net sales for the Eylea and Eylea HD franchise decreased 10% year-over-year to $941 million, marking the first time since fiscal Q2 2018 that the franchise's U.S. quarterly sales fell below $1 billion. This decline was primarily driven by competitive pressures, including from Roche's Vabysmo, and a significant 36% year-over-year drop in sales of the original Eylea formulation. Additionally, regulatory delays related to the FDA's decision on a second contract manufacturer for the Eylea HD pre-filled syringe created investor uncertainty.
2. The Phase 3 trial for fianlimab failed to meet its primary endpoint, leading to a significant stock drop.
In May 2026, Regeneron announced that its Phase 3 trial evaluating fianlimab in combination with cemiplimab as a first-line treatment for advanced melanoma did not achieve statistical significance for the primary endpoint of improved progression-free survival (PFS). This news resulted in a sharp decline of nearly 10% in Regeneron's stock price on May 18, 2026. The trial's failure and the subsequent investor reaction also led to a securities class action lawsuit against the company, alleging that it misrepresented the trial's prospects and risks.
Show more
Regeneron Pharmaceuticals (REGN) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Continued weakness and competitive pressures impacted the Eylea franchise.
In fiscal Q1 2026, reported on April 29, 2026, total U.S. net sales for the Eylea and Eylea HD franchise decreased 10% year-over-year to $941 million, marking the first time since fiscal Q2 2018 that the franchise's U.S. quarterly sales fell below $1 billion. This decline was primarily driven by competitive pressures, including from Roche's Vabysmo, and a significant 36% year-over-year drop in sales of the original Eylea formulation. Additionally, regulatory delays related to the FDA's decision on a second contract manufacturer for the Eylea HD pre-filled syringe created investor uncertainty.
2. The Phase 3 trial for fianlimab failed to meet its primary endpoint, leading to a significant stock drop.
In May 2026, Regeneron announced that its Phase 3 trial evaluating fianlimab in combination with cemiplimab as a first-line treatment for advanced melanoma did not achieve statistical significance for the primary endpoint of improved progression-free survival (PFS). This news resulted in a sharp decline of nearly 10% in Regeneron's stock price on May 18, 2026. The trial's failure and the subsequent investor reaction also led to a securities class action lawsuit against the company, alleging that it misrepresented the trial's prospects and risks.
3. An agreement with the U.S. government on drug pricing introduced long-term macroeconomic uncertainty.
Regeneron entered into an agreement with the U.S. government to lower drug prices, an initiative that, while advocated by the company, may have created investor apprehension regarding future pricing power and revenue stability for its key pharmaceutical products. This macroeconomic factor contributed to a cautious outlook on the company's financial trajectory.
Show less
Stock Movement Drivers
Fundamental Drivers
The -4.3% change in REGN stock from 3/31/2026 to 7/30/2026 was primarily driven by a -11.3% change in the company's Net Income Margin (%).| (LTM values as of) | 3312026 | 7302026 | Change |
|---|---|---|---|
| Stock Price ($) | 771.49 | 738.34 | -4.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14,343 | 15,535 | 8.3% |
| Net Income Margin (%) | 31.4% | 27.9% | -11.3% |
| P/E Multiple | 17.7 | 17.5 | -0.7% |
| Shares Outstanding (Mil) | 103 | 103 | 0.3% |
| Cumulative Contribution | -4.3% |
Market Drivers
3/31/2026 to 7/30/2026| Return | Correlation | |
|---|---|---|
| REGN | -4.3% | |
| Market (SPY) | 14.0% | 15.7% |
| Sector (XLV) | 11.5% | 42.1% |
Fundamental Drivers
The -4.1% change in REGN stock from 12/31/2025 to 7/30/2026 was primarily driven by a -13.3% change in the company's Net Income Margin (%).| (LTM values as of) | 12312025 | 7302026 | Change |
|---|---|---|---|
| Stock Price ($) | 769.79 | 738.34 | -4.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14,248 | 15,535 | 9.0% |
| Net Income Margin (%) | 32.1% | 27.9% | -13.3% |
| P/E Multiple | 17.4 | 17.5 | 0.7% |
| Shares Outstanding (Mil) | 104 | 103 | 0.8% |
| Cumulative Contribution | -4.1% |
Market Drivers
12/31/2025 to 7/30/2026| Return | Correlation | |
|---|---|---|
| REGN | -4.1% | |
| Market (SPY) | 9.1% | 24.6% |
| Sector (XLV) | 6.1% | 51.2% |
Fundamental Drivers
The 41.4% change in REGN stock from 6/30/2025 to 7/30/2026 was primarily driven by a 41.6% change in the company's P/E Multiple.| (LTM values as of) | 6302025 | 7302026 | Change |
|---|---|---|---|
| Stock Price ($) | 522.14 | 738.34 | 41.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14,086 | 15,535 | 10.3% |
| Net Income Margin (%) | 31.9% | 27.9% | -12.8% |
| P/E Multiple | 12.4 | 17.5 | 41.6% |
| Shares Outstanding (Mil) | 107 | 103 | 3.8% |
| Cumulative Contribution | 41.4% |
Market Drivers
6/30/2025 to 7/30/2026| Return | Correlation | |
|---|---|---|
| REGN | 41.4% | |
| Market (SPY) | 21.1% | 17.8% |
| Sector (XLV) | 22.9% | 48.9% |
Fundamental Drivers
The 3.6% change in REGN stock from 6/30/2023 to 7/30/2026 was primarily driven by a 25.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302023 | 7302026 | Change |
|---|---|---|---|
| Stock Price ($) | 712.65 | 738.34 | 3.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 12,370 | 15,535 | 25.6% |
| Net Income Margin (%) | 33.8% | 27.9% | -17.6% |
| P/E Multiple | 18.2 | 17.5 | -3.9% |
| Shares Outstanding (Mil) | 107 | 103 | 4.2% |
| Cumulative Contribution | 3.6% |
Market Drivers
6/30/2023 to 7/30/2026| Return | Correlation | |
|---|---|---|
| REGN | 3.6% | |
| Market (SPY) | 73.2% | 29.7% |
| Sector (XLV) | 29.0% | 49.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| REGN Return | 31% | 14% | 22% | -19% | 9% | -10% | 45% |
| Peers Return | 21% | 20% | -11% | 4% | 15% | 18% | 83% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| REGN Win Rate | 67% | 50% | 58% | 50% | 50% | 43% | |
| Peers Win Rate | 53% | 62% | 38% | 50% | 53% | 63% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| REGN Max Drawdown | -20% | -26% | -17% | -42% | -35% | -26% | |
| Peers Max Drawdown | -19% | -18% | -27% | -23% | -23% | -14% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AMGN, MRK, BMY, ABBV, PFE. See REGN Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/30/2026 (YTD)
How Low Can It Go
| Event | REGN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -29.4% | -18.8% |
| % Gain to Breakeven | 41.5% | 23.1% |
| Time to Breakeven | 161 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -12.6% | -24.5% |
| % Gain to Breakeven | 14.4% | 32.4% |
| Time to Breakeven | 55 days | 427 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -16.7% | -19.2% |
| % Gain to Breakeven | 20.0% | 23.8% |
| Time to Breakeven | 76 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -19.8% | -3.7% |
| % Gain to Breakeven | 24.7% | 3.9% |
| Time to Breakeven | 7 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -36.8% | -12.2% |
| % Gain to Breakeven | 58.2% | 13.9% |
| Time to Breakeven | 1517 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -21.8% | -17.9% |
| % Gain to Breakeven | 27.8% | 21.8% |
| Time to Breakeven | 7 days | 123 days |
In The Past
Regeneron Pharmaceuticals's stock fell -29.4% during the 2025 US Tariff Shock. Such a loss loss requires a 41.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | REGN | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -29.4% | -18.8% |
| % Gain to Breakeven | 41.5% | 23.1% |
| Time to Breakeven | 161 days | 79 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -36.8% | -12.2% |
| % Gain to Breakeven | 58.2% | 13.9% |
| Time to Breakeven | 1517 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -21.8% | -17.9% |
| % Gain to Breakeven | 27.8% | 21.8% |
| Time to Breakeven | 7 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -51.1% | -53.4% |
| % Gain to Breakeven | 104.6% | 114.4% |
| Time to Breakeven | 294 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -24.7% | -8.6% |
| % Gain to Breakeven | 32.9% | 9.5% |
| Time to Breakeven | 6 days | 47 days |
In The Past
Regeneron Pharmaceuticals's stock fell -29.4% during the 2025 US Tariff Shock. Such a loss loss requires a 41.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. is a leading biopharmaceutical company engaged in the discovery, invention, development, manufacture, and commercialization of a broad range of innovative medicines globally. The company focuses on leveraging its scientific platforms to create novel treatments for serious diseases, spanning from chronic conditions and autoimmune disorders to various cancers and infectious diseases.
The company's main product portfolio features several key therapies. EYLEA is a cornerstone product, widely used to treat serious eye conditions such as wet age-related macular degeneration and diabetic macular edema. Dupixent represents another significant offering, addressing allergic and inflammatory diseases like atopic dermatitis and asthma. Regeneron also markets Libtayo for certain types of skin cancer, Praluent for cardiovascular conditions, and Kevzara for rheumatoid arthritis, alongside treatments for rare diseases and infectious agents like the Zaire ebolavirus.
Regeneron's primary customers are patients worldwide suffering from a diverse array of medical conditions. Its medicines serve critical markets in ophthalmology, immunology, oncology, cardiovascular and metabolic health, and infectious and rare diseases. Through ongoing research and strategic collaborations, Regeneron aims to continuously expand its therapeutic reach and bring much-needed treatments to patients facing debilitating and life-threatening illnesses.
AI Analysis | Feedback
Think of them as a major pharmaceutical company like **Merck** or **Novartis**, but with a particularly strong track record for discovering and developing innovative blockbuster drugs in areas like eye disease and immunology.
They are like a leading biotech innovator such as **Amgen**, but with a more diverse portfolio of widely-used treatments, including drugs for conditions like macular degeneration, asthma, and certain cancers.
AI Analysis | Feedback
- EYLEA injection: A treatment for various eye conditions including wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
- Dupixent injection: Used to treat atopic dermatitis and asthma in both adults and pediatric patients.
- Libtayo injection: Prescribed for metastatic or locally advanced cutaneous squamous cell carcinoma.
- Praluent injection: An adult treatment for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.
- REGEN-COV: Developed for the treatment of COVID-19.
- Kevzara solution: A treatment for rheumatoid arthritis in adults.
- Inmazeb injection: Used for infections caused by the Zaire ebolavirus.
- ARCALYST injection: Administered for cryopyrin-associated periodic syndromes.
- ZALTRAP injection: An intravenous infusion to treat metastatic colorectal cancer.
AI Analysis | Feedback
Regeneron Pharmaceuticals (REGN) sells its products primarily to other companies and governmental entities within the healthcare supply chain, rather than directly to individual consumers.
The major customers for Regeneron's pharmaceutical products are typically large pharmaceutical wholesalers and distributors who then supply pharmacies, hospitals, and other healthcare providers. Additionally, government agencies can be significant direct purchasers for certain products, as indicated by the company's agreement with the U.S. Department of Health and Human Services for REGEN-COV.
The major customer companies (pharmaceutical wholesalers) include:
- McKesson Corporation (MCK)
- AmerisourceBergen Corporation (ABC)
- Cardinal Health, Inc. (CAH)
In addition to these wholesalers, the U.S. Department of Health and Human Services is identified as a direct customer for specific products like REGEN-COV.
AI Analysis | Feedback
AI Analysis | Feedback
Leonard S. Schleifer, MD, PhD
Co-Chairman of the Board, President and Chief Executive Officer
Dr. Leonard S. Schleifer co-founded Regeneron Pharmaceuticals in 1988 with the vision of building a science-driven company focused on helping patients. He has served as President and Chief Executive Officer since the company's inception and became Co-Chairman of the Board in June 2023. Prior to founding Regeneron, Dr. Schleifer earned his M.D. and Ph.D. in pharmacology from the University of Virginia, and was a practicing neurologist and professor at Cornell Medical School. He was motivated to start the company due to the lack of effective treatments for serious neurodegenerative diseases.
Christopher Fenimore
Executive Vice President, Finance and Chief Financial Officer
Christopher Fenimore was appointed Executive Vice President, Finance and Chief Financial Officer of Regeneron in January 2025, having initially become CFO in February 2024. He joined Regeneron in 2003 and has held various finance leadership roles within the company, including Senior Vice President, Controller; Vice President, Controller; and Vice President, Financial Planning and Analysis. Before joining Regeneron, Mr. Fenimore served as Vice President of Finance for a biotechnology start-up and held roles in healthcare industry-focused venture capital and investment banking. He began his career as an auditor at KPMG and is a Certified Public Accountant in New York.
George D. Yancopoulos, MD, PhD
Co-Chairman of the Board, President and Chief Scientific Officer
Dr. George D. Yancopoulos is the co-founder, Co-Chairman of the Board, President, and Chief Scientific Officer of Regeneron, which he joined in 1989. He is recognized as a highly successful scientist and drug discoverer, and is a principal inventor and developer of Regeneron's foundational technologies and numerous FDA-approved treatments. Dr. Yancopoulos graduated as valedictorian of the Bronx High School of Science and Columbia College, and earned his M.D. and Ph.D. in Biochemistry and Molecular Biophysics from Columbia University. He left an academic career to co-found Regeneron alongside Dr. Leonard Schleifer.
Joseph J. LaRosa
Executive Vice President, General Counsel and Secretary
Joseph J. LaRosa joined Regeneron in 2011 and currently serves as Executive Vice President, General Counsel and Secretary. Prior to Regeneron, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. His previous experience also includes serving as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc., and holding several senior legal positions at Schering-Plough Corporation, where he was a corporate officer and Vice President, Legal Affairs. Mr. LaRosa received his J.D. degree from New York University School of Law.
Daniel Van Plew
Executive Vice President & General Manager, Industrial Operations and Product Supply
Daniel Van Plew joined Regeneron in 2007 and has served as Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. Before joining Regeneron, he was Executive Vice President, R&D and Technical Operations for Crucell Holland B.V., a global biopharmaceutical company, from 2006 to 2007. He also held positions of increasing responsibility at Chiron Biopharmaceuticals, including Senior Director, Vacaville Operations, and worked in various managerial roles in the health and life sciences practice at Accenture. Mr. Van Plew holds an M.S. in Chemistry from Pennsylvania State University and an M.B.A. from Michigan State University.
AI Analysis | Feedback
Regeneron Pharmaceuticals (REGN) faces several key risks to its business, primarily centered around its blockbuster products and the highly competitive pharmaceutical landscape.
- Erosion of Eylea Revenue due to Patent Expiration and Biosimilar Competition: Regeneron's flagship eye drug, Eylea, is experiencing significant revenue erosion due to the expiration of key patents and the subsequent entry of biosimilar competitors, such as Amgen's Pavblu and Samsung Bioepis' Opuviz. This patent cliff, combined with competition from innovative rival drugs like Roche's Vabysmo, has already led to a decline in Eylea's U.S. net sales. While Regeneron has launched Eylea HD to mitigate these effects, its success is crucial in offsetting the decline, and the company has already faced regulatory setbacks, including an FDA rejection for a prefilled syringe version of Eylea HD due to a manufacturing issue.
- Heavy Reliance on Key Blockbuster Products and the Imperative for Successful Pipeline Development: Regeneron is significantly dependent on the commercial success of a limited number of key products, primarily Eylea and Dupixent, for a substantial portion of its revenue. While Dupixent's patent exclusivity is anticipated to last until 2030/2031, the challenges faced by Eylea underscore the vulnerability of relying heavily on a few top-selling drugs. Therefore, the successful development and commercialization of new product candidates from its clinical pipeline are critically important to offset revenue declines from mature products and drive future growth. Failures in clinical trials, such as the recent Phase III setback for itepekimab, a Dupixent follow-up drug, pose a significant risk to the company's growth prospects.
- Intensified Market Competition and Regulatory/Manufacturing Hurdles: The biopharmaceutical industry is characterized by intense competition from both established pharmaceutical companies and emerging biotech firms across all therapeutic areas. Products like Dupixent, while currently successful, are facing increasing competitive pressures from new rivals entering the market or in advanced stages of development. Furthermore, Regeneron operates in a heavily regulated environment, and challenges in navigating complex regulatory approval processes, including unexpected actions or delays from authorities like the FDA, can significantly impact the availability and commercial potential of its products. Manufacturing and supply chain disruptions or quality control issues also represent ongoing operational risks that can delay product launches and affect financial results.
AI Analysis | Feedback
AI Analysis | Feedback
EYLEA (Aflibercept)
EYLEA targets multiple ophthalmic conditions, each representing a substantial market:
- Wet Age-Related Macular Degeneration (wAMD): The global market size for wet age-related macular degeneration was estimated at USD 10.1 billion in 2024 and is projected to reach USD 20 billion by 2034. In the 7 major markets (US, EU4, UK, and Japan), the wet AMD market reached USD 9,528.8 million in 2024 and is expected to grow to USD 18,317.5 million by 2035.
- Diabetic Macular Edema (DME): The global diabetic macular edema market size was valued at USD 3.33 billion in 2024 and is projected to reach USD 4.34 billion by 2032. Another estimate indicates the global DME market is expected to grow from USD 5.50 billion in 2024 to USD 8.64 billion by 2035.
- Diabetic Retinopathy (DR): The global diabetic retinopathy market size was estimated at USD 9.48 billion in 2024 and is expected to grow to USD 13.77 billion by 2030. Other projections place the global diabetic retinopathy market at USD 10.23 billion in 2025, reaching USD 18.93 billion by 2035.
- Macular Edema following Retinal Vein Occlusion (RVO): The global retinal vein occlusion market size was calculated at USD 2.82 billion in 2024 and is predicted to reach approximately USD 5.45 billion by 2034.
Dupixent (Dupilumab)
Dupixent is a significant product for allergic and inflammatory conditions:
- Overall Dupixent Market: The global Dupixent market size was estimated at USD 14.15 billion in 2024 and is projected to reach USD 27.58 billion by 2033.
- Atopic Dermatitis: The global atopic dermatitis drugs market size was estimated at USD 17.64 billion in 2024 and is projected to reach USD 29.88 billion by 2030. Other analyses suggest the global atopic dermatitis drug market size, calculated at USD 15.92 billion in 2025, is predicted to increase to approximately USD 33.42 billion by 2035.
Libtayo (Cemiplimab)
Libtayo addresses certain cancers:
- Cutaneous Squamous Cell Carcinoma (CSCC) Treatment: The global cutaneous squamous cell carcinoma treatment market size is estimated at USD 13.69 billion in 2024 and is projected to reach approximately USD 27.54 billion by 2034.
Praluent (Alirocumab)
Praluent targets cholesterol management:
- Heterozygous Familial Hypercholesterolemia (HeFH) Management: The global heterozygous familial hypercholesterolemia management market size is expected to grow from USD 12.04 billion in 2025 to USD 20.12 billion by 2030.
Kevzara (Sarilumab)
Kevzara is used for autoimmune diseases:
- Rheumatoid Arthritis (RA) Therapeutics: The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033. Another report valued the global market for rheumatoid arthritis therapies at USD 28.5 billion in 2024, estimated to increase to USD 41.1 billion by 2030.
AI Analysis | Feedback
AI Analysis | Feedback
Share Repurchases
- Regeneron Pharmaceuticals authorized a $3 billion share repurchase program in November 2021, with an additional $1.8 million remaining from a previous $1.5 billion program.
- The company repurchased $2.235 billion in 2023, $2.603 billion in 2024, and $3.439 billion in 2025.
- As of February 2026, approximately $1.486 billion remained available for future share repurchases under authorized programs.
Outbound Investments
- Regeneron made a Series C investment in Truveta on January 13, 2025.
- The company invested in Enlaza (Series A, April 30, 2024) and Vyriad (Series B, May 17, 2022).
- In Q2 2025, Regeneron in-licensed rights to a late-stage dual GLP-1/GIP receptor agonist, and in Q3 2025, made an $80 million upfront payment for a license agreement with Hansoh Pharmaceuticals Group Company Limited.
Capital Expenditures
- Capital expenditures were $718.6 million in 2023, $755.9 million in 2024, and $898.4 million in 2025.
- Regeneron plans to invest approximately $1.1 billion to $1.3 billion in 2026 for facility expansions.
- The company has committed to over $7 billion in U.S. investments, including expansions in Tarrytown and Rensselaer, NY, and a new agreement to double U.S. large-scale manufacturing capacity, and an additional $2 billion for a new bulk manufacturing facility in Saratoga Springs, NY. These investments aim to significantly expand manufacturing capacity and support ongoing manufacturing operations.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 193.60 |
| Mkt Cap | 175.5 |
| Rev LTM | 56,003 |
| Op Inc LTM | 13,406 |
| FCF LTM | 10,462 |
| FCF 3Y Avg | 10,929 |
| CFO LTM | 12,383 |
| CFO 3Y Avg | 12,900 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.1% |
| Rev Chg 3Y Avg | 4.0% |
| Rev Chg Q | 5.7% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | 22.6% |
| Op Inc Chg 3Y Avg | 17.2% |
| Op Mgn LTM | 27.5% |
| Op Mgn 3Y Avg | 23.0% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 28.1% |
| CFO/Rev 3Y Avg | 30.3% |
| FCF/Rev LTM | 23.1% |
| FCF/Rev 3Y Avg | 25.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 175.5 |
| P/S | 4.9 |
| P/Op Inc | 19.0 |
| P/EBIT | 16.2 |
| P/E | 22.9 |
| P/CFO | 17.1 |
| Total Yield | 6.2% |
| Dividend Yield | 2.6% |
| FCF Yield 3Y Avg | 5.5% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.2% |
| 3M Rtn | 10.5% |
| 6M Rtn | 16.6% |
| 12M Rtn | 37.0% |
| 3Y Rtn | 26.8% |
| 1M Excs Rtn | 7.0% |
| 3M Excs Rtn | 10.5% |
| 6M Excs Rtn | 10.6% |
| 12M Excs Rtn | 19.2% |
| 3Y Excs Rtn | -38.1% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Collaboration revenue | 7,331 | 6,058 | 5,503 | 4,914 | 3,673 |
| EYLEA ® | 2,748 | 4,767 | 5,720 | 6,265 | 5,792 |
| EYLEA HD ® | 1,637 | 1,201 | 166 | 0 | 0 |
| Libtayo ® | 945 | 787 | 539 | 374 | 306 |
| Other revenue | 703 | 515 | 536 | 365 | 281 |
| Libtayo | 508 | 430 | 324 | 73 | 0 |
| Praluent ® | 262 | 242 | 182 | 130 | 170 |
| Evkeeza ® | 162 | 126 | 77 | 49 | 18 |
| Inmazeb ® | 37 | 77 | 70 | 3 | 0 |
| Other products | 10 | 0 | 0 | ||
| ARCALYST ® | 2 | ||||
| REGEN-COV ® | 5,828 | ||||
| Total | 14,343 | 14,202 | 13,117 | 12,173 | 16,072 |
| $ Mil | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|
| Contract Manufacturing | 3 | 5 | 3 | 1 |
| Research and Development | -104 | -127 | -90 | |
| R & D | -33 | |||
| Reconciling | 8 | |||
| Total | -100 | -122 | -87 | -23 |
| $ Mil | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|
| Research and Development | 57 | 96 | 111 | 92 | 76 |
| Contract Manufacturing | 0 | 4 | 7 | 13 | 12 |
| Total | 57 | 100 | 118 | 105 | 88 |
Price Behavior
| Market Price | $738.34 | |
| Market Cap ($ Bil) | 76.8 | |
| First Trading Date | 04/02/1991 | |
| Distance from 52W High | -8.9% | |
| 50 Days | 200 Days | |
| DMA Price | $641.02 | $707.39 |
| DMA Trend | up | down |
| Distance from DMA | 15.2% | 4.4% |
| 3M | 1YR | |
| Volatility | 35.5% | 33.7% |
| Downside Capture | 16.30 | 42.51 |
| Upside Capture | 34.22 | 68.23 |
| Correlation (SPY) | 7.2% | 15.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.04 | 0.21 | 0.52 | 0.56 | 0.45 | 0.60 |
| Up Beta | 1.07 | 1.53 | 1.49 | 1.36 | 0.79 | 0.61 |
| Down Beta | 0.44 | -0.60 | -0.98 | -0.23 | -0.24 | 0.41 |
| Up Capture | -42% | -28% | -7% | 20% | 55% | 29% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 13 | 19 | 27 | 56 | 123 | 379 |
| Down Capture | -58% | 61% | 110% | 90% | 65% | 94% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 8 | 22 | 36 | 69 | 128 | 370 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with REGN | |
|---|---|---|---|---|
| REGN | 33.2% | 33.7% | 0.89 | - |
| Sector ETF (XLV) | 23.3% | 15.9% | 1.13 | 48.3% |
| Equity (SPY) | 17.8% | 12.9% | 1.01 | 17.0% |
| Gold (GLD) | 23.3% | 28.1% | 0.73 | 9.9% |
| Commodities (DBC) | 29.4% | 19.7% | 1.19 | -22.7% |
| Real Estate (VNQ) | 12.7% | 13.9% | 0.62 | 20.6% |
| Bitcoin (BTCUSD) | -46.2% | 42.9% | -1.32 | 8.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with REGN | |
|---|---|---|---|---|
| REGN | 4.9% | 31.0% | 0.19 | - |
| Sector ETF (XLV) | 6.3% | 15.0% | 0.24 | 50.8% |
| Equity (SPY) | 12.7% | 17.1% | 0.57 | 32.5% |
| Gold (GLD) | 17.4% | 18.4% | 0.76 | 4.3% |
| Commodities (DBC) | 9.0% | 19.5% | 0.35 | -2.9% |
| Real Estate (VNQ) | 2.8% | 18.9% | 0.05 | 28.3% |
| Bitcoin (BTCUSD) | 14.5% | 53.3% | 0.45 | 9.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with REGN | |
|---|---|---|---|---|
| REGN | 6.8% | 32.2% | 0.28 | - |
| Sector ETF (XLV) | 10.0% | 16.6% | 0.49 | 51.9% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 37.2% |
| Gold (GLD) | 11.6% | 16.1% | 0.59 | 3.8% |
| Commodities (DBC) | 7.2% | 18.0% | 0.32 | 5.0% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 25.7% |
| Bitcoin (BTCUSD) | 57.8% | 66.2% | 0.98 | 8.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 7/30/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/29/2026 | -6.2% | -4.0% | -14.9% |
| 1/30/2026 | -1.1% | 2.3% | 5.6% |
| 10/28/2025 | 11.8% | 9.7% | 34.7% |
| 8/1/2025 | 2.5% | 2.6% | 6.6% |
| 4/29/2025 | -6.9% | -1.2% | -3.0% |
| 2/4/2025 | 4.5% | 3.5% | 3.2% |
| 10/31/2024 | -9.2% | -11.5% | -18.7% |
| 8/1/2024 | 1.3% | -1.1% | 9.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 15 | 11 | 14 |
| # Negative | 9 | 13 | 10 |
| Median Positive | 3.5% | 4.7% | 5.9% |
| Median Negative | -3.7% | -3.3% | -6.5% |
| Max Positive | 11.8% | 9.7% | 34.7% |
| Max Negative | -9.2% | -11.5% | -18.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/29/2026 | -6.2% | -4.0% | -14.9% |
| 1/30/2026 | -1.1% | 2.3% | 5.6% |
| 10/28/2025 | 11.8% | 9.7% | 34.7% |
| 8/1/2025 | 2.5% | 2.6% | 6.6% |
| 4/29/2025 | -6.9% | -1.2% | -3.0% |
| 2/4/2025 | 4.5% | 3.5% | 3.2% |
| 10/31/2024 | -9.2% | -11.5% | -18.7% |
| 8/1/2024 | 1.3% | -1.1% | 9.2% |
| 5/2/2024 | 3.8% | 5.8% | 8.5% |
| 2/2/2024 | -1.3% | -1.2% | 1.4% |
| 11/2/2023 | 3.5% | 4.0% | 3.0% |
| 8/3/2023 | 5.4% | 7.3% | 12.9% |
| 5/4/2023 | -6.1% | -6.7% | -7.9% |
| 2/3/2023 | 4.3% | -0.9% | 3.9% |
| 11/3/2022 | -0.2% | 0.3% | 3.5% |
| 8/3/2022 | 5.9% | 8.2% | 1.1% |
| 5/4/2022 | 0.1% | -6.9% | -4.5% |
| 2/4/2022 | 0.4% | -0.4% | -0.3% |
| 11/4/2021 | -0.7% | -4.6% | -2.6% |
| 8/5/2021 | 3.7% | 4.7% | 16.3% |
| 5/6/2021 | 3.4% | 5.1% | 6.1% |
| 2/5/2021 | 0.0% | -1.7% | -7.1% |
| 11/5/2020 | 0.3% | -3.3% | -16.1% |
| 8/5/2020 | -3.7% | -7.6% | -5.9% |
| SUMMARY STATS | |||
| # Positive | 15 | 11 | 14 |
| # Negative | 9 | 13 | 10 |
| Median Positive | 3.5% | 4.7% | 5.9% |
| Median Negative | -3.7% | -3.3% | -6.5% |
| Max Positive | 11.8% | 9.7% | 34.7% |
| Max Negative | -9.2% | -11.5% | -18.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/30/2026 | 10-Q |
| 03/31/2026 | 04/29/2026 | 10-Q |
| 12/31/2025 | 02/04/2026 | 10-K |
| 09/30/2025 | 10/28/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/05/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/05/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/06/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/30/2026 | 10-Q |
| 03/31/2026 | 04/29/2026 | 10-Q |
| 12/31/2025 | 02/04/2026 | 10-K |
| 09/30/2025 | 10/28/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/05/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/05/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/06/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 02/07/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 02/08/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/05/2020 | 10-Q |
| 03/31/2020 | 05/05/2020 | 10-Q |
| 12/31/2019 | 02/07/2020 | 10-K |
| 09/30/2019 | 11/05/2019 | 10-Q |
Recent Forward Guidance
Updated 7/8/2026Latest: Q1 2026 Earnings Reported 4/29/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 GAAP R&D | 6.45 Bil | 6.57 Bil | 6.68 Bil | 0 | Affirmed | Guidance: 6.57 Bil for 2026 | |
| 2026 Non-GAAP R&D | 5.90 Bil | 6.00 Bil | 6.10 Bil | 0 | Affirmed | Guidance: 6.00 Bil for 2026 | |
| 2026 GAAP SG&A | 2.86 Bil | 2.95 Bil | 3.04 Bil | 0 | Affirmed | Guidance: 2.95 Bil for 2026 | |
| 2026 Non-GAAP SG&A | 2.50 Bil | 2.58 Bil | 2.65 Bil | 0 | Affirmed | Guidance: 2.58 Bil for 2026 | |
| 2026 GAAP gross margin on net product sales | 77.0% | 77.5% | 78.0% | -2.0% | Lowered | Guidance: 79.5% for 2026 | |
| 2026 Non-GAAP gross margin on net product sales | 83.0% | 83.5% | 84.0% | 0 | Affirmed | Guidance: 83.5% for 2026 | |
| 2026 GAAP COCM | 955.00 Mil | 995.00 Mil | 1.03 Bil | 1.5% | Raised | Guidance: 980.00 Mil for 2026 | |
| 2026 Non-GAAP COCM | 940.00 Mil | 980.00 Mil | 1.02 Bil | 0 | Affirmed | Guidance: 980.00 Mil for 2026 | |
| 2026 Capital expenditures | 1.10 Bil | 1.15 Bil | 1.20 Bil | -4.2% | Lowered | Guidance: 1.20 Bil for 2026 | |
| 2026 GAAP effective tax rate | 12.0% | 13.0% | 14.0% | 0 | Affirmed | Guidance: 13.0% for 2026 | |
| 2026 Non-GAAP effective tax rate | 13.0% | 14.0% | 15.0% | 0 | Affirmed | Guidance: 14.0% for 2026 | |
Prior: Q4 2025 Earnings Reported 1/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 GAAP R&D | 6.45 Bil | 6.57 Bil | 6.68 Bil | 14.9% | Higher New | Guidance: 5.71 Bil for 2025 | |
| 2026 Non-GAAP R&D | 5.90 Bil | 6.00 Bil | 6.10 Bil | 15.9% | Higher New | Guidance: 5.17 Bil for 2025 | |
| 2026 GAAP SG&A | 2.86 Bil | 2.95 Bil | 3.04 Bil | 5.0% | Higher New | Guidance: 2.81 Bil for 2025 | |
| 2026 Non-GAAP SG&A | 2.50 Bil | 2.58 Bil | 2.65 Bil | 6.2% | Higher New | Guidance: 2.42 Bil for 2025 | |
| 2026 GAAP gross margin on net product sales | 79.0% | 79.5% | 80.0% | ||||
| 2026 Non-GAAP gross margin on net product sales | 83.0% | 83.5% | 84.0% | ||||
| 2026 COCM | 940.00 Mil | 980.00 Mil | 1.02 Bil | 0.5% | Higher New | Guidance: 975.00 Mil for 2025 | |
| 2026 Capital expenditures | 1.10 Bil | 1.20 Bil | 1.30 Bil | 37.9% | Higher New | Guidance: 870.00 Mil for 2025 | |
| 2026 GAAP effective tax rate | 12.0% | 13.0% | 14.0% | ||||
| 2026 Non-GAAP effective tax rate | 13.0% | 14.0% | 15.0% | ||||
Q3 2025 Earnings Reported 10/28/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 GAAP R&D | 5.68 Bil | 5.71 Bil | 5.75 Bil | -0.2% | Lowered | Guidance: 5.72 Bil for 2025 | |
| 2025 Non-GAAP R&D | 5.15 Bil | 5.17 Bil | 5.20 Bil | 0.5% | Raised | Guidance: 5.15 Bil for 2025 | |
| 2025 GAAP SG&A | 2.77 Bil | 2.81 Bil | 2.85 Bil | -2.3% | Lowered | Guidance: 2.88 Bil for 2025 | |
| 2025 Non-GAAP SG&A | 2.40 Bil | 2.42 Bil | 2.45 Bil | -3.0% | Lowered | Guidance: 2.50 Bil for 2025 | |
| 2025 COCM | 950.00 Mil | 975.00 Mil | 1.00 Bil | -4.9% | Lowered | Guidance: 1.02 Bil for 2025 | |
| 2025 Capital Expenditures | 850.00 Mil | 870.00 Mil | 890.00 Mil | -4.9% | Lowered | Guidance: 915.00 Mil for 2025 | |
Insider Activity
Updated 7/7/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ryan, Arthur F | Direct | Sell | 7072026 | 650.15 | 200 | 130,030 | 11,249,545 | Form | |
| 2 | Ryan, Arthur F | Direct | Sell | 5042026 | 705.24 | 100 | 70,524 | 12,343,781 | Form | |
| 3 | Ryan, Arthur F | Direct | Sell | 4032026 | 777.27 | 100 | 77,727 | 13,682,333 | Form | |
| 4 | Ryan, Arthur F | Direct | Sell | 3032026 | 785.50 | 100 | 78,550 | 13,905,627 | Form | |
| 5 | Zoghbi, Huda Y | Direct | Sell | 2232026 | 781.33 | 1,638 | 1,279,812 | 1,330,598 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ryan, Arthur F | Direct | Sell | 7072026 | 650.15 | 200 | 130,030 | 11,249,545 | Form | |
| 2 | Ryan, Arthur F | Direct | Sell | 5042026 | 705.24 | 100 | 70,524 | 12,343,781 | Form | |
| 3 | Ryan, Arthur F | Direct | Sell | 4032026 | 777.27 | 100 | 77,727 | 13,682,333 | Form | |
| 4 | Ryan, Arthur F | Direct | Sell | 3032026 | 785.50 | 100 | 78,550 | 13,905,627 | Form | |
| 5 | Zoghbi, Huda Y | Direct | Sell | 2232026 | 781.33 | 1,638 | 1,279,812 | 1,330,598 | Form | |
| 6 | Pitofsky, Jason | SVP Controller | Direct | Sell | 2112026 | 778.52 | 2,036 | 1,585,058 | 3,325,819 | Form |
| 7 | Ryan, Arthur F | Direct | Sell | 2112026 | 778.53 | 100 | 77,853 | 13,860,098 | Form | |
| 8 | Bassler, Bonnie L | Direct | Sell | 11242025 | 750.00 | 760 | 570,000 | 1,161,000 | Form | |
| 9 | Pitofsky, Jason | VP Controller | Direct | Sell | 11102025 | 651.43 | 431 | 280,766 | 2,757,503 | Form |
| 10 | Poon, Christine A | Direct | Sell | 10312025 | 654.27 | 6,500 | 4,252,745 | 1,538,840 | Form |
Investor Activity (13F)
Updated Jul 31, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Bronte Capital Management Pty Ltd. | $133.5 Mil | 14.2% | 51 | Hold | 13F |
| Mcdonald Capital Investors Inc/Ca | $159.1 Mil | 10.9% | 21 | Hold | 13F |
| Davern Capital Partners, LP | $34.6 Mil | 9.5% | 17 | TRIM -14.5% | 13F |
| Jia Investment Alliance PTE. LTD. | $52.0 Mil | 5.4% | 24 | Hold | 13F |
| Sound Shore Management Inc /CT/ | $116.6 Mil | 3.9% | 40 | TRIM -14.2% | 13F |
| Active Manager |
|---|
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | As Of | Filing |
|---|---|---|---|---|---|---|
| Catalio Capital Management, LP | $23.0 Mil | 4.1% | 45 | Exited | Dec 31, 2025 | 13F |
| Sector Gamma AS | $5.5 Mil | 1.3% | 36 | Exited | Dec 31, 2025 | 13F |
| Davern Capital Partners, LP | $34.6 Mil | 9.5% | 17 | TRIM -14.5% | Mar 31, 2026 | 13F |
| Sound Shore Management Inc /CT/ | $116.6 Mil | 3.9% | 40 | TRIM -14.2% | Mar 31, 2026 | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Mcdonald Capital Investors Inc/Ca | $159.1 Mil | 10.9% | 21 | Hold | 13F |
| Bronte Capital Management Pty Ltd. | $133.5 Mil | 14.2% | 51 | Hold | 13F |
| Sound Shore Management Inc /CT/ | $116.6 Mil | 3.9% | 40 | TRIM -14.2% | 13F |
| Jia Investment Alliance PTE. LTD. | $52.0 Mil | 5.4% | 24 | Hold | 13F |
| Davern Capital Partners, LP | $34.6 Mil | 9.5% | 17 | TRIM -14.5% | 13F |
Regeneron Pharmaceuticals — Investor Video Playlist
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.